Next Article in Journal
Rapid Detection of Escherichia coli O157 and Shiga Toxins by Lateral Flow Immunoassays
Next Article in Special Issue
Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia—A Spotlight in Reality
Previous Article in Journal
Fumonisin B1 (FB1) Induces Lamellar Separation and Alters Sphingolipid Metabolism of In Vitro Cultured Hoof Explants
Previous Article in Special Issue
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Toxins 2016, 8(4), 91; doi:10.3390/toxins8040091

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery

1
Department of Urology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, Taipei 24205, Taiwan
2
Department of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, Taipei 23702, Taiwan
3
Department of Biomedical Engineering, Chung Yuan Christian University, Chung-Li 32023, Taiwan
4
Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien 97002, Taiwan
*
Author to whom correspondence should be addressed.
Academic Editor: Hann-Chorng Kuo
Received: 2 February 2016 / Revised: 16 March 2016 / Accepted: 18 March 2016 / Published: 25 March 2016
(This article belongs to the Special Issue Botulinum Toxin A on Lower Urinary Tract Dysfunction)
View Full-Text   |   Download PDF [237 KB, uploaded 25 March 2016]

Abstract

Overactive bladder (OAB) symptoms increase with age and involve several comorbidities. OnabotulinumtoxinA (BoNT-A) intravesical injection is a treatment choice for patients who are intolerant of or refractory to antimuscarinics. However, the increased risk of urinary tract infection and elevated post-void residual (PVR) volume post-treatment require resolution. Male sex, baseline PVR > 100 mL, and comorbidities are independent risk factors of adverse events (AEs) such as acute urinary retention (AUR). Intravesical BoNT-A injection is safe and effective for OAB patients with frailty, medical comorbidities such as Parkinson’s disease (PD), chronic cerebrovascular accidents (CVA), dementia, or diabetes, or a history of prior lower urinary tract surgery (prostate or transvaginal sling surgery). Post-treatment, 60% of frail elderly patients had a PVR volume > 150 mL and 11% had AUR. Although intravesical BoNT-A injection is safe for PD patients, CVA patients had higher strain voiding rates. Diabetic patients were at increased risk of large PVR urine volume and general weakness post-treatment. Treatment results were similar between patients with and without a history of prostate or transvaginal sling surgery. Possible AEs and bladder management strategies should be conveyed to patients before treatment. Careful patient selection is important, and therapeutic safety and efficacy should be carefully balanced. View Full-Text
Keywords: botulinum toxin; Type A; urinary bladder; overactive; frail elderly; comorbidity botulinum toxin; Type A; urinary bladder; overactive; frail elderly; comorbidity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Liao, C.-H.; Wang, C.-C.; Jiang, Y.-H. Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery. Toxins 2016, 8, 91.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top